TTFields: Where does all the skepticism come from?

Neuro-Oncology

Volumn 18, Issue 3, 2016, Pages 303-305

  Wick, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE;

ARTICLE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; DRUG IMPLANTATION; ELECTRIC FIELD; ELECTROSTIMULATION THERAPY; GLIOBLASTOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR TREATING FIELD; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); HUMAN; MULTIMODALITY CANCER THERAPY;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS;

EID: 84960081834     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now012     Document Type: Article

References (14)

1. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. JAMA. 2015;314(23): 2535-2543.
2. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.
3. Kirson ED, Dbalý V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 2007;104(24):10152-10157.
4. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88.
5. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-996.
6. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.
7. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
8. Stupp R, Hegi ME, Gorlia T, et al. European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team.: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with ethylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100-1108.
9. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352:997-1003.
10. Wick W, Weller M, van den Bent M, et al. MGMT testing-The challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014;10(7):372-385.
11. Stupp R,Wong ET, Scott CB, et al. Interim analysis of the EF-14 trial: A prospective, multicenter trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. SNO 2014 late-breaking abstract, November 15, 2014.
12. Diasio RB. Adjuvant chemotherapy for adenocarcinoma of the lung-is the standard of care ready for change? N Engl J Med. 2004;350(17):1777-1779.
13. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.
14. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.